From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin
Group
Name
Sample size
Compound
Dosage
A 0
Placebo
n = 15
N/A (CMC capsule b.i.d)
A 1
Dose 1
UP446
250 mg/day (125 mg b.i.d.)
A 2
Dose 2
500 mg/day (250 mg b.i.d.)
A 3
Dose 3
Celecoxib
200 mg/day (100 mg b.i.d.)